Scrutinize the data and tweets to envisage if the closing price of $amgn will swell or contract at 2017-09-20. Please affirm either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-09-06,-0.4,0.4,-1.1,0.9,0.9,-0.7,-2.6,-3.5,-3.8,-3.6,-3.5
2017-09-07,-1.2,1.1,-1.9,1.3,1.3,-1.2,-3.2,-4.4,-4.8,-4.7,-4.7
2017-09-08,0.2,1.1,-0.6,-0.0,-0.0,-0.9,-2.5,-3.9,-4.4,-4.5,-4.5
2017-09-11,-2.1,0.1,-2.1,3.2,3.2,-3.2,-4.7,-6.2,-6.9,-7.2,-7.2
2017-09-12,-2.1,0.0,-2.2,2.4,2.4,-4.0,-6.0,-7.6,-8.6,-9.0,-9.1
2017-09-13,0.1,0.7,-1.0,-0.7,-0.7,-2.1,-4.4,-6.3,-7.5,-8.1,-8.2
2017-09-14,-0.6,0.9,-0.9,-0.1,-0.1,-1.0,-3.4,-5.4,-6.9,-7.6,-7.8
2017-09-15,1.2,1.2,-0.6,-1.0,-1.0,0.7,-1.9,-3.8,-5.3,-6.2,-6.5
2017-09-18,0.7,1.1,-0.2,-0.5,-0.5,1.3,-0.9,-2.7,-4.3,-5.3,-5.8
2017-09-19,0.3,0.6,-0.3,-0.1,-0.1,0.8,-0.4,-2.1,-3.8,-4.9,-5.5

2017-09-06: $amgn tezepelumab significantly reduced asthma exacerbations f¡­ |$amgn: amgen and astrazeneca (azn) results from the pathway phase 2b trial of tezepelumab that showed a... |commented on  $adms $alny 
2017-09-07: $amgn news. see what flies tomorrow...|rt AT_USER $amgn new data demonstrate aimovig erenumab reduced monthly migraine days in patients who failed previous therapies |$chrs $amgn coherus biosciences i
2017-09-08: rt AT_USER video  stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn |rt AT_USER health care and biotech stocks are on a tear this year, and carter and AT_USER think $amgn has even 
2017-09-09: $amgn - breakout watch #182.8, target - 184, 191. stop: 178. short potential targets - 177, 169, 164. cover: 183|rt AT_USER video  stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn
2017-09-10: rt AT_USER my video   stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn |rt AT_USER my video   stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn |rt AT_USER my 
2017-09-11: big call buyers  $bhp $teva $splk $mgm $oi $mac $intc $arry $wfc $snap $bidu $efx $cbs $qcom $amgn $nke $idti $ko|rt AT_USER mon-wed: morgan stanley 150 healthcare webcasts $abbv $agn $alxn $amgn $bii
2017-09-12: clean breakout for $amgn on the monthly chart. looks like it wants $200. measured move targets $220. |rt AT_USER $amgn looks pretty serious this time |big call buyers  $bac $amtd $mu $ttm $twtr $wsm $
2017-09-13: shkreli gets maximum security prison! $vrx $mnk $goog $ko $twtr $fold $amzn $ko $pep $jazz $amgn $myl $mrk $crm¡­ |investors buy amgen inc. $amgn on weakness |investors buy amgen inc. $amgn on weaknes
2017-09-14: $amgn max pain=175.00. maturity=09/15/2017. previous close=0.00 #maxpain #options |rt AT_USER $amgn gets AT_USER approval of mvasi, a biosimilar avastin and the 1st biosimilar of a cancer drug: |rt AT
2017-09-15: rt AT_USER video  stock mkt analysis 9/15/17 $spy $qqq $iwm $smh $ibb $xxii $amgn $tsla |rt AT_USER video  stock mkt analysis 9/15/17 $spy $qqq $iwm $smh $ibb $xxii $amgn $tsla |rt AT_USER video  stoc
2017-09-16: the fda just set the stage for amgen, fueled by a milestone biosimilar approval $amgn |midday most tweeted big caps, check out gambiste top 10: $xom $ko $bac $hd $googl $c $goog $orcl $amgn $pbr |incr
2017-09-17: join the signal service endorsed by #topfivetraders  $msft, $intc, $amgn, $googl , $abx, $fb¡­ |$amgn - breakout watch #191.3, target - 201. stop: 185. short potential targets - 180.6, 175.7, 172. cov
2017-09-18: $sny &amp; $amgn, eyeing boost for #pcsk9 use, tout benefits for #diabetes patients #pharma #biotech #cholesteroldrug |$sny &amp; $regn #dupixent scores potential sales boost as $abbv candidate threat
2017-09-19: quote: "only now might rnai finally be on the verge of breaking through..." $arwr $amgn |large-cap value farming $afl $tgt $amgn $aapl $amzn $nflx $fb $googl | &lt; review of this fantastic traders te
Answer:
Scrutinize the data and tweets to envisage if the closing price of $amgn will swell or contract at 2017-09-20. Please affirm either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-09-06,-0.4,0.4,-1.1,0.9,0.9,-0.7,-2.6,-3.5,-3.8,-3.6,-3.5
2017-09-07,-1.2,1.1,-1.9,1.3,1.3,-1.2,-3.2,-4.4,-4.8,-4.7,-4.7
2017-09-08,0.2,1.1,-0.6,-0.0,-0.0,-0.9,-2.5,-3.9,-4.4,-4.5,-4.5
2017-09-11,-2.1,0.1,-2.1,3.2,3.2,-3.2,-4.7,-6.2,-6.9,-7.2,-7.2
2017-09-12,-2.1,0.0,-2.2,2.4,2.4,-4.0,-6.0,-7.6,-8.6,-9.0,-9.1
2017-09-13,0.1,0.7,-1.0,-0.7,-0.7,-2.1,-4.4,-6.3,-7.5,-8.1,-8.2
2017-09-14,-0.6,0.9,-0.9,-0.1,-0.1,-1.0,-3.4,-5.4,-6.9,-7.6,-7.8
2017-09-15,1.2,1.2,-0.6,-1.0,-1.0,0.7,-1.9,-3.8,-5.3,-6.2,-6.5
2017-09-18,0.7,1.1,-0.2,-0.5,-0.5,1.3,-0.9,-2.7,-4.3,-5.3,-5.8
2017-09-19,0.3,0.6,-0.3,-0.1,-0.1,0.8,-0.4,-2.1,-3.8,-4.9,-5.5

2017-09-06: $amgn tezepelumab significantly reduced asthma exacerbations f¡­ |$amgn: amgen and astrazeneca (azn) results from the pathway phase 2b trial of tezepelumab that showed a... |commented on  $adms $alny 
2017-09-07: $amgn news. see what flies tomorrow...|rt AT_USER $amgn new data demonstrate aimovig erenumab reduced monthly migraine days in patients who failed previous therapies |$chrs $amgn coherus biosciences i
2017-09-08: rt AT_USER video  stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn |rt AT_USER health care and biotech stocks are on a tear this year, and carter and AT_USER think $amgn has even 
2017-09-09: $amgn - breakout watch #182.8, target - 184, 191. stop: 178. short potential targets - 177, 169, 164. cover: 183|rt AT_USER video  stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn
2017-09-10: rt AT_USER my video   stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn |rt AT_USER my video   stock mkt video analysis 9/8/17 $spy $gnrc $qqq $nflx $iwm $ibb $amgn |rt AT_USER my 
2017-09-11: big call buyers  $bhp $teva $splk $mgm $oi $mac $intc $arry $wfc $snap $bidu $efx $cbs $qcom $amgn $nke $idti $ko|rt AT_USER mon-wed: morgan stanley 150 healthcare webcasts $abbv $agn $alxn $amgn $bii
2017-09-12: clean breakout for $amgn on the monthly chart. looks like it wants $200. measured move targets $220. |rt AT_USER $amgn looks pretty serious this time |big call buyers  $bac $amtd $mu $ttm $twtr $wsm $
2017-09-13: shkreli gets maximum security prison! $vrx $mnk $goog $ko $twtr $fold $amzn $ko $pep $jazz $amgn $myl $mrk $crm¡­ |investors buy amgen inc. $amgn on weakness |investors buy amgen inc. $amgn on weaknes
2017-09-14: $amgn max pain=175.00. maturity=09/15/2017. previous close=0.00 #maxpain #options |rt AT_USER $amgn gets AT_USER approval of mvasi, a biosimilar avastin and the 1st biosimilar of a cancer drug: |rt AT
2017-09-15: rt AT_USER video  stock mkt analysis 9/15/17 $spy $qqq $iwm $smh $ibb $xxii $amgn $tsla |rt AT_USER video  stock mkt analysis 9/15/17 $spy $qqq $iwm $smh $ibb $xxii $amgn $tsla |rt AT_USER video  stoc
2017-09-16: the fda just set the stage for amgen, fueled by a milestone biosimilar approval $amgn |midday most tweeted big caps, check out gambiste top 10: $xom $ko $bac $hd $googl $c $goog $orcl $amgn $pbr |incr
2017-09-17: join the signal service endorsed by #topfivetraders  $msft, $intc, $amgn, $googl , $abx, $fb¡­ |$amgn - breakout watch #191.3, target - 201. stop: 185. short potential targets - 180.6, 175.7, 172. cov
2017-09-18: $sny &amp; $amgn, eyeing boost for #pcsk9 use, tout benefits for #diabetes patients #pharma #biotech #cholesteroldrug |$sny &amp; $regn #dupixent scores potential sales boost as $abbv candidate threat
2017-09-19: quote: "only now might rnai finally be on the verge of breaking through..." $arwr $amgn |large-cap value farming $afl $tgt $amgn $aapl $amzn $nflx $fb $googl | &lt; review of this fantastic traders te
Answer:+Rise